Methods of treating complement-associated disorders with anti-C5a antibodies
First Claim
Patent Images
1. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, comprises:
- (a) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
140;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
96;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
142;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
144; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;
(b) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21; and
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
67; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;
(c) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
156;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
157;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
158;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
160;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
161; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
162;
(d) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
164;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
165;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
166;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
168;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
169; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
170;
(e) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
172;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
173;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
174;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
176;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
177; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
178;
(f) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
84;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
85;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
86;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
116; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;
(g) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
88;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
89;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
90;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
120; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
121;
(h) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
99;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
100;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
101;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
126; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
127;
(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
113;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
(j) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
110;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
111;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
136;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
137; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
138;
(k) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
105;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
106;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
107;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
124; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;
(l) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;
(m) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;
(n) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
or(o) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture'"'"'s syndrome, and chronic obstructive pulmonary disease.
-
Citations
16 Claims
-
1. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, comprises:
-
(a) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
140;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
96;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
142;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
144; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(b) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21; and
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
67; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(c) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
156;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
157;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
158;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
160;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
161; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
162;(d) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
164;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
165;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
166;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
168;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
169; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
170;(e) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
172;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
173;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
174;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
176;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
177; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
178;(f) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
84;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
85;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
86;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
116; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(g) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
88;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
89;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
90;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
120; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
121;(h) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
99;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
100;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
101;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
126; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
127;(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
113;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;(j) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
110;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
111;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
136;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
137; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
138;(k) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
105;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
106;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
107;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
124; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(l) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(m) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(n) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
or(o) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47. - View Dependent Claims (2, 11, 12, 13, 14, 15)
-
-
3. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, comprises:
-
(a) heavy and light chains, wherein the light chain comprises the amino acid sequence depicted in SEQ ID NO;
17, 36, or 40;(b) heavy and light chains, wherein the heavy chain comprises the amino acid sequence depicted in SEQ ID NO;
25, 33, 44, or 49;(c) heavy and light chain variable regions, wherein the light chain variable region comprises the amino acid sequence depicted in SEQ ID NO;
19, 37, or 42;
or(d) heavy and light chain variable regions, wherein the heavy chain variable region comprises the amino acid sequence depicted in SEQ ID NO;
27 or 45. - View Dependent Claims (4, 5, 6, 7)
-
-
8. A method for treating a complement-associated disorder, the method comprising administering to a human in need thereof, an antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, comprises:
-
(a) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
19 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
27;(b) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
25;(c) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
33;(d) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
37 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
27;(e) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
36 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
33;(f) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
42 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
27;(g) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
40 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
33;(h) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
19 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
45;(i) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
44;(j) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
17 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
49;(k) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
37 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
45;(l) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
36 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
49;(m) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
42 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
45;
or(n) a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
40 and a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO;
49. - View Dependent Claims (9, 10)
-
-
16. A method for treating a human afflicted with a C5a-associated complement disorder, the method comprising administering to the human:
- (i) at least 1 mg of an antibody or antigen-binding fragment thereof per kg body weight of the human to thereby partially or completely bind and sequester nanogram levels of free C5a for at least 12 days or (ii) in an amount sufficient to (a) achieve molar Cmax values substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester pathophysiologic levels of free C5a, wherein the antibody, or antigen-binding fragment thereof, comprises;
(a) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
140;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
96;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
142;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
144; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(b) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21; and
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
67; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(c) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
156;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
157;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
158;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
160;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
161; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
162;(d) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
164;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
165;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
166;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
168;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
169; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
170;(e) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
172;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
173;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
174;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
176;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
177; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
178;(f) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
84;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
85;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
86;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
116; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(g) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
88;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
89;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
90;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
120; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
121;(h) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
99;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
100;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
101;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
119;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
126; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
127;(i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
113;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;(j) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
110;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
111;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
136;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
137; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
138;(k) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
105;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
106;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
107;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
115;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
124; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
117;(l) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(m) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
29; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
30;(n) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
21;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47;
or(o) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
20;
a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
38;
a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
22;
a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
28;
a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
46; and
a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
47.
- (i) at least 1 mg of an antibody or antigen-binding fragment thereof per kg body weight of the human to thereby partially or completely bind and sequester nanogram levels of free C5a for at least 12 days or (ii) in an amount sufficient to (a) achieve molar Cmax values substantially lower than the molar physiologic concentration of uncleaved hC5 and (b) partially or completely bind and sequester pathophysiologic levels of free C5a, wherein the antibody, or antigen-binding fragment thereof, comprises;
Specification